Small cell lung cancer: treatment review (Q36458604)

14 August 2017

1 reference

title

Small cell lung cancer: treatment review (English)

1 reference

14 August 2017

1 reference

Samantha Cooper

1

1 reference

PubMed ID

16635081

14 August 2017

Stephen G Spiro

series ordinal

2

1 reference

14 August 2017

1 May 2006

1 reference

14 August 2017

1 reference

14 August 2017

11

1 reference

14 August 2017

3

1 reference

14 August 2017

241-248

1 reference

14 August 2017

Small cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Can we predict very short term survival in small cell lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Lung cancer--where are we today? Current advances in staging and nonsurgical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Chemoradiotherapy for lung cancer: current status and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Combined chemoradiotherapy in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Maintenance chemotherapy for small cell lung cancer: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Second-line chemotherapy and its evaluation in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Emerging role of weekly topotecan in recurrent small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Prophylactic cranial irradiation revisited: cost-effectiveness and quality of life in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Should aggressive surgery ever be part of the management of small cell lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Treatment of lung cancer in elderly part II: small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Treatment of small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

High-dose cyclophosphamide with autologous marrow transplantation for small cell carcinoma of the bronchus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

Localized small-cell lung cancer: which type of thoracic radiotherapy and which time schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00850.X

10.1111/J.1440-1843.2006.00850.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16635081